Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease
CNS Drugs · 2025
DOI: 10.1007/s40263-024-01139-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift CNS Drugs, 2025. Verfasst von Samuel Frank und 12 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center/Harvard Medical School, 330 Brookline Ave., Kirstein 228, Boston, MA, 02215, USA. sfrank2@bidmc.harvard.edu. Hauptthemen laut MEDLINE: Tetrabenazine, Huntington Disease, Chorea, Adrenergic Uptake Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Teva Branded Pharmaceutical Products R&D, Inc..
Abstract (Originalsprache)
Huntington disease (HD) is a progressive neurodegenerative disease that causes psychiatric and neurological symptoms, including involuntary and irregular muscle movements (chorea). Chorea can disrupt activities of daily living, pose safety issues, and may lead to social withdrawal. The vesicular monoamine transporter 2 inhibitors tetrabenazine, deutetrabenazine, and valbenazine are approved treatments that can reduce chorea. This post hoc analysis was conducted to evaluate safety and efficacy among participants who received high-dosage deutetrabenazine treatment (> 48 mg/d) in ARC-HD, an open-label study that assessed long-term safety and efficacy of deutetrabenazine for the treatment of chorea in HD in adults. ARC-HD was a single-arm, two-cohort, open-label study. Participants either successfully completed the First-HD study or switched overnight from tetrabenazine to deutetrabenazine. Participants were dosed with deutetrabenazine in a response-driven manner (maximum 72 mg/d allowed). For the current analysis, exposure-adjusted incidence rates (EAIRs) for adverse events of interest were analyzed according to daily dosage (≤ 48 mg/d versus > 48 mg/d), and total maximal chorea (TMC) scores were analyzed by cohort during the stable-dose period. In total, 116 of the 119 participants enrolled in ARC-HD entered the stable-dose period, where no apparent differences were seen in EAIRs when receiving deutetrabenazine dosages ≤ 48 mg/d (exposure = 177.7 person-years) compared with > 48 mg/d (exposure = 74.1 person-years). Similar results were found among the subset of participants who received deutetrabenazine dosages > 48 mg/d at least once during the study (n = 49, 42%) when their dosage was ≤ 48 mg/d (exposure = 37.9 person-years) versus > 48 mg/d (74.1 person-years). Efficacy analyses were conducted for participants who had TMC scores available (rollover cohort, n = 77; switch cohort, n = 35). For most participants, the lowest deutetrabenazine dosage needed to achieve a TMC response (≥ 30% improvement from baseline) was between 24 and 48 mg/d in both the rollover (n = 57, 74.0%) and switch (n = 16, 46.0%) cohorts. Whereas the dosage needed for a TMC response was independent of baseline TMC score in the rollover cohort, participants with higher baseline TMC scores in the switch cohort required higher dosages to achieve a TMC response during the trial. In this open-label, long-term study, some participants received deutetrabenazine dosing > 48 mg/d to achieve adequate chorea control. There was no new safety concern or incremental change in the safety profile between dosages of ≤ 48 mg/d and > 48 mg/d. These results include dosages that have not been approved for clinical use, however, they increase our understanding of safety and tolerability of deutetrabenazine doses. ARC-HD (ClinicalTrials.gov identifier: NCT01897896); First-HD (ClinicalTrials.gov identifier: NCT01795859). ARC-HD was a medical study in which participants took a medicine called deutetrabenazine. Deutetrabenazine is used to treat unplanned movements known as chorea, which happen in participants who have Huntington disease. At the start of the ARC-HD study, all participants took 6 milligrams per day (mg/d) of the medicine. Each week, the doctor could give them more medicine, but not more than 72 mg/d. The doctor checked if the medicine helped to lower their chorea and if any safety concerns occurred. The highest amount of the medicine that is allowed in the USA is 48 mg/d. Some participants took more than that. We wanted to learn more about the safety (side effects) and the chorea in participants who took more than 48 mg/d. Participants who took more than 48 mg/d had no new side effects of interest. They also reported the same number of side effects as participants who took 48 mg/d or less. For most participants, the lowest amount of medicine they needed to lower their chorea was between 24 and 48 mg/d.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Beth Israel Deaconess Medical Center/Harvard Medical School, 330 Brookline Ave., Kirstein 228, Boston, MA, 02215, USA. sfrank2@bidmc.harvard.edu.
- University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Huntington Study Group, Rochester, NY, USA.
- Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
- University of Rochester, Rochester, NY, USA.
- Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA.
Förderung
- Teva Branded Pharmaceutical Products R&D, Inc.
Zitieren
APA
Frank, S., Testa, C. M., Goldstein, J., Kayson, E., Leavitt, B. R., Oakes, D., O'Neill, C., Whaley, J., Gross, N., Chaijale, N., Barash, S., Gordon, M. F., & Huntington Study Group/ARC-HD Investigators and Coordinators (2025). Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease. CNS Drugs. https://doi.org/10.1007/s40263-024-01139-3
Vancouver
Frank S, Testa CM, Goldstein J, Kayson E, Leavitt BR, Oakes D, et al. Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease. CNS Drugs. 2025. doi:10.1007/s40263-024-01139-3
BibTeX
@article{Frank2025,
author = {Frank, Samuel and Testa, Claudia M and Goldstein, Jody and Kayson, Elise and Leavitt, Blair R and Oakes, David and O'Neill, Christine and Whaley, Jacquelyn and Gross, Nicholas and Chaijale, Nayla and Barash, Steve and Gordon, Mark Forrest and Huntington Study Group/ARC-HD Investigators and Coordinators, Huntington Study Group/ARC-HD Investigators and Coordinators},
title = {Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease},
journal = {CNS Drugs},
year = {2025},
doi = {10.1007/s40263-024-01139-3}
}
EUVIMED